Senescence-associated protein p400 is a prognostic marker in renal cell carcinoma

Macher-Goeppinger,Stephan; Bermejo,Justo   Lorenzo; Schirmacher,Peter; Pahernik,Sascha; Hohenfellner,Markus; Roth,Wilfried

doi:10.3892/or.2013.2698

Senescence-associated protein p400 is a prognostic marker in renal cell carcinoma

Authors:
- Stephan Macher-Goeppinger
- Justo Lorenzo Bermejo
- Peter Schirmacher
- Sascha Pahernik
- Markus Hohenfellner
- Wilfried Roth
View Affiliations

Affiliations: Institute of Pathology, University Hospital of Heidelberg, D-69120 Heidelberg, Germany, Institute of Medical Biometry and Informatics, University of Heidelberg, D-69120 Heidelberg, Germany, Department of Urology, University Hospital of Heidelberg, D-69120 Heidelberg, Germany
Published online on: August 26, 2013 https://doi.org/10.3892/or.2013.2698
Pages: 2245-2253

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mutations of the von Hippel-Lindau (VHL) tumor suppressor gene cause hereditary and sporadic renal cell carcinomas (RCCs). The best characterized function of VHL protein is suppression of the α subunit of hypoxia inducible factor (HIF). Additional VHL functions have been reported, including induction of senescence upon loss of VHL mediated by downregulation of the chromatin remodeling factor p400. Induction of senescence either by oncogene activation or inactivation of tumor suppressors is considered a critical feature of mammalian cells by which to suppress tumorigenesis. In the present study, we investigated the relationship between the expression of p400 and patient survival following RCC diagnosis taking advantage of a large and well-documented series of RCC patients with long-term follow-up information. The expression of p400 was measured by immunohistochemistry using a tissue microarray containing tumor tissue samples from 868 RCC patients. Chi-squared tests, Kaplan-Meier curves, Cox regression models and Spearman's rank correlation estimates were used to investigate the possible relationship between p400 expression and Ki-67 proliferative index, clinical and pathological characteristics and patient survival. Complete loss of p400 expression was detected in 64% of all tumor specimens, and decreased p400 expression was associated with advanced tumor stage, higher grade of malignancy and regional lymph node metastasis. Among well-differentiated RCCs, high proliferation (Ki-67 index >10) was found in 12% of carcinomas with an increased p400 expression, compared to 5% of RCCs with decreased p400 expression. Multiple Cox regression indicated that patients with low proliferative tumors and increased p400 expression had a 60% lower cancer-specific mortality risk compared to those affected by low proliferative RCCs with decreased p400 expression. In summary, patients affected by highly proliferative tumors with decreased p400 expression exhibit a poor prognosis by multiple Cox regression. Our data suggest that the highly proliferative, decreased-p400 subgroup of RCCs represents tumors that are characterized by a loss of the tumor-suppressive mechanism of senescence.

View Figures

View References

1	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
2	Merino MJ, Eccles DM, Linehan WM, et al: Familial renal cell carcinoma. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Eble JN, Sauter G, Epstein J and Sesterhenn IA: IARC Press; Lyon: pp. 15–22. 2004
3	Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:271–275. 1999. View Article : Google Scholar : PubMed/NCBI
4	Kaelin WG Jr and Ratcliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 30:393–402. 2008. View Article : Google Scholar : PubMed/NCBI
5	Raval RR, Lau KW, Tran MGB, et al: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 25:5675–5686. 2005. View Article : Google Scholar : PubMed/NCBI
6	Shen C, Beroukhim R, Schumacher SE, et al: Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov. 1:222–235. 2011.PubMed/NCBI
7	Roe JS and Youn HD: The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle. 5:2054–2056. 2006. View Article : Google Scholar : PubMed/NCBI
8	Thoma CR, Frew IJ, Hoerner CR, Montani M, Moch H and Krek W: pVHL and GSK3β are components of a primary cilium-maintenance signalling network. Nat Cell Biol. 9:588–595. 2007.
9	Lolkema MP, Mans DA, Snijckers CM, et al: The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2. FEBS Lett. 581:4571–4576. 2007. View Article : Google Scholar : PubMed/NCBI
10	Roe JS, Kim HR, Hwang IY, Cho EJ and Youn HD: von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Oncogene. 30:3127–3138. 2011. View Article : Google Scholar : PubMed/NCBI
11	Young AP and Kaelin WG Jr: Senescence triggered by the loss of the VHL tumor suppressor. Cell Cycle. 7:1709–1712. 2008. View Article : Google Scholar : PubMed/NCBI
12	Xu Y, Sun Y, Jiang X, et al: The p400 ATPase regulates nucleosome stability and chromatin ubiquitination during DNA repair. J Cell Biol. 191:31–43. 2010. View Article : Google Scholar : PubMed/NCBI
13	Chan HM, Narita M, Lowe SW and Livingston DM: The p400 E1A-associated protein is a novel component of the p53 --> p21 senescence pathway. Genes Dev. 19:196–201. 2005. View Article : Google Scholar : PubMed/NCBI
14	Samuelson AV, Narita M, Chan HM, et al: p400 is required for E1A to promote apoptosis. J Biol Chem. 280:21915–21923. 2005. View Article : Google Scholar : PubMed/NCBI
15	Flinterman MB, Mymryk JS, Klanrit P, et al: p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing. Oncogene. 26:6863–6874. 2007. View Article : Google Scholar : PubMed/NCBI
16	van Diest PJ, van der Wall E and Baak JPA: Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 57:675–681. 2004.PubMed/NCBI
17	Spyratos F, Ferrero-Poüs M, Trassard M, et al: Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer. 94:2151–2159. 2002. View Article : Google Scholar : PubMed/NCBI
18	de Riese WT, Crabtree WN, Allhoff EP, et al: Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol. 11:1804–1808. 1993.PubMed/NCBI
19	Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO and Green AR: MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat. 127:591–599. 2011. View Article : Google Scholar : PubMed/NCBI
20	Rioux-Leclercq N, Turlin B, Bansard J, et al: Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 55:501–505. 2000. View Article : Google Scholar : PubMed/NCBI
21	Scarpa A, Mantovani W, Capelli P, et al: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 23:824–833. 2010. View Article : Google Scholar
22	Michaloglou C, Vredeveld LCW, Soengas MS, et al: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 436:720–724. 2005. View Article : Google Scholar : PubMed/NCBI
23	Macher-Goeppinger S, Aulmann S, Tagscherer KE, et al: Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin Cancer Res. 15:650–659. 2009. View Article : Google Scholar : PubMed/NCBI
24	Dupont Jensen J, Laenkholm AV, Knoop A, et al: PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 17:667–677. 2011.
25	Linehan WM, Srinivasan R and Schmidt LS: The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 7:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
26	Baldewijns MM, van Vlodrop IJH, Vermeulen PB, Soetekouw PM, van Engeland M and de Bruïne AP: VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 221:125–138. 2010. View Article : Google Scholar : PubMed/NCBI
27	Young AP, Schlisio S, Minamishima YA, et al: VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 10:361–369. 2008. View Article : Google Scholar : PubMed/NCBI
28	Welford SM, Dorie MJ, Li X, Haase VH and Giaccia AJ: Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol Cell Biol. 30:4595–4603. 2010. View Article : Google Scholar : PubMed/NCBI
29	Mack FA, Patel JH, Biju MP, Haase VH and Simon MC: Decreased growth of Vhl^−/− fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27. Mol Cell Biol. 25:4565–4578. 2005.PubMed/NCBI
30	Courtois-Cox S, Genther Williams SM, Reczek EE, et al: A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell. 10:459–472. 2006. View Article : Google Scholar : PubMed/NCBI
31	Chen Z, Trotman LC, Shaffer D, et al: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436:725–730. 2005. View Article : Google Scholar : PubMed/NCBI
32	Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16^INK4a. Cell. 88:593–602. 1997. View Article : Google Scholar : PubMed/NCBI
33	Kuilman T, Michaloglou C, Mooi WJ and Peeper DS: The essence of senescence. Genes Dev. 24:2463–2479. 2010. View Article : Google Scholar : PubMed/NCBI
34	Gurova KV, Hill JE, Razorenova OV, Chumakov PM and Gudkov AV: p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res. 64:1951–1958. 2004. View Article : Google Scholar : PubMed/NCBI
35	Burrows AE, Smogorzewska A and Elledge SJ: Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci USA. 107:14280–14285. 2010. View Article : Google Scholar : PubMed/NCBI
36	Varela I, Tarpey P, Raine K, et al: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 469:539–542. 2011. View Article : Google Scholar : PubMed/NCBI
37	Dalgliesh GL, Furge K, Greenman C, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 463:360–363. 2010. View Article : Google Scholar
38	Lin HK, Chen Z, Wang G, et al: Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature. 464:374–379. 2010. View Article : Google Scholar
39	Nardella C, Clohessy JG, Alimonti A and Pandolfi PP: Pro-senescence therapy for cancer treatment. Nat Rev Cancer. 11:503–511. 2011. View Article : Google Scholar : PubMed/NCBI